Per Wester - NOACs; advances and limitations in real world

www.laaocclusion.org Heart & Brain Summit 2017
New oral anticoagulants or NOACs, with favorable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. There are still limitations associated. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for treatment. The focus on NOACs has shifted to the practical approach and management in real life.